Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers
Authors:
- 25 January 2017
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 37 (3) , 249-257
Abstract
Background Liposomal bupivacaine is indicated for administration into the surgical site to produce post-surgical analgesia. Objectives The objectives of this study were to characterize the pharmacokinetic and safety profiles of liposomal bupivacaine following a repeated dose in healthy volunteers. Methods Healthy adults were assigned to receive liposomal bupivacaine via subcutaneous infiltration in a single 266 mg dose (cohort 1) or in two 266 mg doses, with the second dose given immediately, 24, 48, or 72 h after the first dose (cohorts 2–5). Pharmacokinetic parameters were estimated from blood samples collected up to day 14. Subjects were monitored for adverse events and assessed for neurologic function, cardiac function, and infiltration area abnormalities. Results Twelve subjects were assigned to each cohort. The mean ± standard deviation maximum observed plasma concentration (C max) of bupivacaine after a single dose was 129 ± 47 ng/mL. The mean C max after the second dose was higher, but always less than double the C max for cohort 1. The highest individual C max (589 ng/mL) was observed in a subject who received the second dose 24 h after the first dose (cohort 4), but was well below the reported thresholds for neurotoxicity and cardiac toxicity (2000 and 4000 ng/mL, respectively). A single and repeated dose were well-tolerated, and there were no clinically meaningful findings regarding neurologic examinations and electrocardiography. Conclusions The mean C max following a repeated dose of liposomal bupivacaine remained well below accepted values for central nervous system and cardiac toxicity. Liposomal bupivacaine was well-tolerated and revealed no clinically important safety signals. ClinicalTrials.gov Identifier NCT02210247.Keywords
Funding Information
- Pacira Pharmaceuticals
This publication has 16 references indexed in Scilit:
- Liposome Bupivacaine Femoral Nerve Block for Postsurgical Analgesia after Total Knee ArthroplastyAnesthesiology, 2016
- 2015Journal of Surgical Orthopaedic Advances, 2015
- A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplastyThe Knee, 2012
- Safety Evaluation of EXPAREL (DepoFoam Bupivacaine) Administered by Repeated Subcutaneous Injection in Rabbits and Dogs: Species ComparisonJournal of Drug Delivery, 2011
- ASRA Practice Advisory on Local Anesthetic Systemic ToxicityRegional Anesthesia & Pain Medicine, 2010
- Pharmacokinetics of Bupivacaine during Postoperative Epidural InfusionAnesthesiology, 2002
- Double-blind comparison of ropivacaine 7.5 mg ml–1 with bupivacaine 5 mg ml–1 for sciatic nerve blockBritish Journal of Anaesthesia, 2001
- A comparison of the cardiovascular effects of levobupivacaine and rac‐bupivacaine following intravenous administration to healthy volunteersBritish Journal of Clinical Pharmacology, 1998
- Bupivacaine Enantiomer Pharmacokinetics After Intercostal Neural Blockade in Liver Transplantation PatientsAnesthesia & Analgesia, 1995
- THE EFFECT OF LOCAL ANAESTHETICS ON THE CENTRAL CIRCULATION AND RESPIRATION IN MAN AND DOG1),2)Acta Anaesthesiologica Scandinavica, 1968